10-Q: Rafael Holdings Q2 Loss Widens on R&D Surge, Cash Declines

Rafael Holdings reported a wider net loss for the second fiscal quarter and first half of 2026, driven by significantly increased research and development expenses primarily from its Cyclo acquisition, despite a gain from debt settlement.

Summary

• Net loss attributable to Rafael Holdings, Inc. increased to $6.4 million for the three months ended January 31, 2026, from $4.6 million in the prior year.
• For the six months ended January 31, 2026, net loss attributable to Rafael Holdings, Inc. increased to $16.2 million, from $13.6 million in the prior year.
• Total revenue for the three months ended January 31, 2026, increased to $0.2 million from $0.1 million, primarily due to product revenue from the Cyclo merger and Rafael Medical Devices.
• Total revenue for the six months ended January 31, 2026, increased to $0.5 million from $0.2 million.
• Research and development expenses surged to $4.5 million for the quarter and $12.0 million for the six months, largely due to the consolidation of Cyclo.
• Cash and cash equivalents decreased by $15.0 million to $37.8 million as of January 31, 2026, from $52.8 million at July 31, 2025.
• A material weakness in internal control over financial reporting was identified at the acquired Cyclo subsidiary, related to accruals and expenses.
• The company settled an $8.5 million creditor liability for $0.4 million in February 2026, expecting a $3.5 million non-cash gain in the next quarter.
• All Employee Retention Credits (ERC) and accrued interest, totaling $1.2 million, were received during the six months ended January 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging quarter with widening losses and increased cash burn, primarily due to heavy R&D investment in the acquired Cyclo subsidiary. While the debt settlement and FDA clearance are positive operational developments, the overall financial performance indicates significant ongoing capital requirements and the identified material weakness in internal controls adds a layer of concern.

Positives

• Product revenue increased significantly due to the Cyclo merger and FDA clearance of Rafael Medical Devices' VECTR System.
• No goodwill impairment was recorded in the current period, compared to a $3.1 million impairment in the prior year.
• Successful settlement of an $8.5 million creditor liability for $0.4 million, expected to result in a $3.5 million non-cash gain in the next quarter.
• All Employee Retention Credits (ERC) and accrued interest, totaling $1.2 million, were fully collected.
• General and administrative expenses decreased for the three months ended January 31, 2026, by $0.3 million.

Negatives

• Net loss attributable to Rafael Holdings, Inc. widened to $6.4 million for the quarter and $16.2 million for the six months, compared to $4.6 million and $13.6 million respectively in the prior year.
• Research and development expenses increased substantially by $3.6 million for the quarter and $9.7 million for the six months, primarily due to the Cyclo acquisition.
• Cash and cash equivalents decreased by $15.0 million to $37.8 million, indicating increased cash burn from operations.
• Operating activities used $14.3 million in cash for the six months, a significant increase from $5.4 million in the prior year.
• Interest income decreased due to the sale of available-for-sale securities and lower interest-earning balances.

Risks

• The company's ability to identify attractive opportunities in the marketplace for Rafael Medical Devices' future products.
• The successful ongoing remediation of the material weakness in internal control over financial reporting at Cyclo is not assured, and additional material weaknesses could develop or be identified.
• The possibility of any future payments to the Creditor from proceeds of Cornerstone assets, revenues, or other value, although the company believes this possibility is remote.
• Foreign currency exchange risk due to revenues from Israeli tenants being in New Israeli Shekel, though currently not material.
• Reliance on the successful completion of the pivotal Phase 3 clinical trial for Trappsol Cyclo and subsequent regulatory approval and market entry.
• The need to secure external investment and partnerships for Forme Therapeutics (SHMT program).
• LipoMedix is exploring strategic options for its lead candidate, indicating uncertainty in its development path.
• Cornerstone's optimal operational direction is still under review.

Future Outlook

The company's primary focus and goals are to finish development of Trappsol Cyclo through the completion of its ongoing pivotal Phase 3 clinical trial and bring that product to regulatory approval and market, and to expand its investment portfolio through opportunistic and strategic investments, including in therapeutics, that address high unmet medical needs. The company is currently evaluating its other holdings to ensure the future focus of its resources are on core assets and specifically Trappsol Cyclo's clinical and development efforts. Rafael Medical Devices' development of future products will depend upon the success of the VECTR System and the company's ability to identify attractive opportunities in the marketplace. The company expects its cash and cash equivalents to be sufficient to meet its obligations for at least the next 12 months and does not anticipate paying dividends until achieving sustainable profitability and retaining certain minimum cash reserves.

Management Comments

• "Our primary focus and goals are to finish development of Trappsol Cyclo through the completion of its ongoing pivotal Phase 3 clinical trial and bring that product to regulatory approval and market, and to expand its investment portfolio through opportunistic and strategic investments, including in therapeutics, that address high unmet medical needs."
• "We are currently evaluating our other holdings to ensure the future focus of our resources are on core assets and specifically Trappsol Cyclos clinical and development efforts."
• "We expect the balance of cash and cash equivalents to be sufficient to meet our obligations for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q."

Industry Context

StockSavvy.ai notes that the significant increase in R&D expenses following the Cyclo merger is typical for biotechnology companies advancing a lead candidate (Trappsol Cyclo) into pivotal Phase 3 trials, reflecting the high costs associated with late-stage clinical development. The FDA clearance for Rafael Medical Devices' VECTR System positions the company to capitalize on the growing demand for minimally invasive surgical instruments in orthopedics. The streamlining of Barer Institute and strategic review of Cornerstone indicate a broader industry trend towards focusing resources on core, high-potential assets in a capital-constrained environment.

Comparison to Industry Standards

• The R&D expenditure increase of 427% for the quarter and 495% for the six months in the Healthcare segment, primarily due to the Cyclo acquisition and its Phase 3 trial for NPC1, is consistent with the substantial investment required for late-stage drug development in rare diseases. For example, companies like Sarepta Therapeutics (Duchenne muscular dystrophy) or BioMarin Pharmaceutical (rare genetic diseases) often report multi-million dollar quarterly R&D costs for their pivotal trials, with similar percentage increases seen when a lead candidate enters late-stage development.
• The FDA 510(k) clearance for Rafael Medical Devices' VECTR System for carpal and cubital tunnel release is a positive milestone, comparable to similar clearances received by medical device companies like Stryker or Zimmer Biomet for new surgical surgical instruments, which can significantly open market access and are critical for product commercialization.
• The cash burn from operating activities of $14.3 million over six months is high relative to the company's current revenue, but not uncommon for a clinical-stage biotech company heavily investing in R&D. This burn rate would be closely scrutinized by investors, similar to how early-stage biotechs like Editas Medicine or CRISPR Therapeutics manage their cash runway while advancing gene therapies, often requiring subsequent capital raises.

Management Changes

Corporate Governance

Legal Proceedings

• The company may from time to time be subject to legal proceedings that arise in the ordinary course of business, but does not expect any to have a material adverse effect on results of operations, cash flows, or financial condition.

Related Party Transactions

• IDT Corporation (related party through common ownership and some common members of management) billed the company approximately $69 thousand for services during the three months ended January 31, 2026, and $157 thousand for the six months ended January 31, 2026.
• IDT Corporation owed the company approximately $175 thousand for office rent and parking as of January 31, 2026.
• Related party rental income represented approximately 13% of the company's total revenue for both the three and six months ended January 31, 2026.
• Howard S. Jonas (Chairman of the Board, Former Chief Executive Officer) and certain related parties purchased 16,386,020 shares of Class B common stock in a private placement for approximately $21.0 million, representing the unsubscribed portion of a $25.0 million rights offering.
• The company invested $500,000 in NINA Medical Ltd. for Series Seed Preferred Shares and warrants, and an additional $250,000 in a Simple Agreement for Future Equity (SAFE); Howard S. Jonas holds an indirect investment in NINA and serves as the Seed Director.

Stakeholder Impact

• Shareholders: Experience dilution from the rights offering and stock-based compensation. Increased R&D expenses and widening losses impact profitability, but potential for future growth from Trappsol Cyclo and other pipeline assets. Debt settlement provides a non-cash gain.
• Employees: Impacted by management changes (Dr. Goldberg, N. Scott Fine). Stock-based compensation plans are in place. Layoffs occurred in the Infusion Technology segment in the prior year.
• Customers: Rafael Medical Devices' VECTR System clearance offers new product availability for minimally invasive surgeries. Day Three Labs Manufacturing's asset sale may affect some customers of its cannabinoid ingredient manufacturing business.
• Creditors: A major creditor's $8.5 million liability was settled for $0.4 million, significantly reducing the company's debt burden to this party.

Next Steps

• Complete the ongoing pivotal Phase 3 clinical trial for Trappsol Cyclo.
• Seek regulatory approval and market entry for Trappsol Cyclo.
• Expand the investment portfolio through opportunistic and strategic investments in therapeutics addressing high unmet medical needs.
• Continue evaluating other holdings to focus resources on core assets and Trappsol Cyclo's development.
• LipoMedix to continue exploring strategic options for its lead candidate, including potential licensing, collaborations, and investigator-initiated studies.
• Barer Institute to primarily operate as an entity holding interest in two cancer-focused opportunities (Ludwig Institute and Forme Therapeutics).
• Review Cornerstone's current efforts, prospects, and available resources to determine optimal operational direction.
• Rafael Medical Devices' future product development depends on the success of the VECTR System and identifying attractive market opportunities.
• Remediate the material weakness in internal control over financial reporting at Cyclo, including integrating vendor/AP management, accrual processes, developing analytical review, and clinical trial accrual estimation.
• Complete the final purchase accounting for the Cyclo merger within the one-year measurement period.

Key Dates

Recommendation

Rafael Holdings presents a mixed picture. The significant increase in R&D expenses, driven by the Cyclo acquisition and its pivotal Phase 3 trial for Trappsol Cyclo, is a necessary investment for a biotech company aiming for a breakthrough in a rare disease. The FDA clearance for the VECTR System and the substantial debt settlement are positive operational and financial developments. However, the widening net losses, increased cash burn, and identified material weakness in internal controls at Cyclo introduce considerable risk and uncertainty. While the long-term potential of Trappsol Cyclo is compelling, the current financial performance and operational challenges suggest a "hold" recommendation, advising investors to monitor the progress of the Phase 3 trial, the remediation of internal controls, and the company's cash runway closely before making further investment decisions.

Keywords

Biotechnology, Pharmaceuticals, Medical Devices, Niemann-Pick Disease Type C1, NPC1, Trappsol Cyclo, Clinical Trials, Phase 3, FDA Clearance, VECTR System, Orthopedics, Cancer Metabolism, Corporate Governance, SEC Filing, Quarterly Report, R&D Expenses, Cash Flow, Liquidity, Debt Settlement, Internal Controls, Related Party Transactions